Core Viewpoint - The company is proposing a 2025 restricted stock incentive plan aimed at enhancing talent retention and competitiveness in the industry, particularly by including foreign employees as part of the incentive program [2][3][4] Group 1: Eligibility and Compliance - The company has confirmed its eligibility to implement the stock incentive plan, adhering to relevant laws and regulations, including the Company Law and Securities Law [2][4] - The plan excludes individuals who have been deemed inappropriate candidates by the stock exchange or the China Securities Regulatory Commission (CSRC) within the last 12 months [2] - The incentive plan's design and approval process comply with the necessary legal frameworks, ensuring no infringement on the interests of the company and its shareholders [4] Group 2: Incentive Targets - The incentive plan includes key personnel such as Chen Xiaolan, who is a company director and holds over 5% of the company's shares, highlighting her significant role in management [3] - The plan does not include independent directors or other major shareholders, ensuring a focus on operational management rather than ownership interests [3] - The company will publicly disclose the names and positions of the incentive targets at least 10 days prior to the shareholders' meeting [3] Group 3: Plan Approval and Implementation - The implementation of the incentive plan is contingent upon approval from the shareholders' meeting, emphasizing the need for corporate governance [4] - The plan aims to align the interests of management and shareholders, thereby enhancing operational efficiency and supporting sustainable development [4]

Group 1 - The core viewpoint of the article is the legal opinion regarding Shenzhen Kaili Biomedical Technology Co., Ltd.'s 2025 Restricted Stock and Stock Option Incentive Plan, which aims to establish a long-term incentive mechanism to attract and retain talent while aligning the interests of shareholders, the company, and employees [2][4][6] - The incentive plan includes a total of 5.8818 million shares, accounting for approximately 1.36% of the company's total share capital at the time of the announcement [7][10] - The plan consists of two parts: the second category of restricted stock incentive plan and the stock option incentive plan, with specific conditions for granting and vesting [6][10] Group 2 - The company is a publicly listed entity with a registered address in Shenzhen, engaged in the development and production of medical devices and related software [4][8] - The company has been in operation since its initial public offering on April 6, 2017, under the stock code "300633" [4] - The legal opinion confirms that the company meets the necessary conditions for implementing the stock incentive plan and does not fall under any prohibitive circumstances as outlined in relevant regulations [5][10] Group 3 - The vesting conditions for the restricted stock include performance targets based on net profit growth rates over the years 2025 to 2028, with specific percentage increases required for each vesting period [19][23] - The granting price for the restricted stock is set at no less than 15.93 yuan per share, determined based on the average trading price prior to the announcement [17][18] - The plan outlines a comprehensive assessment system at the company, departmental, and individual levels to evaluate performance and determine the vesting of shares [24][26]

证券代码：300633 证券简称：开立医疗 深圳开立生物医疗科技股份有限公司 （草案） 声明 本公司及董事会全体成员保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 本公司所有激励对象承诺，公司因信息披露文件中有虚假记载、误导性陈述 或者重大遗漏，导致不符合授予权益或权益归属/行权安排的，激励对象应当自 相关信息披露文件被确认存在虚假记载、误导性陈述或者重大遗漏后，将由公司 特别提示 一、《深圳开立生物医疗科技股份有限公司 2025 年限制性股票与股票期权 激励计划（草案）》（以下简称"本激励计划"）系依据《中华人民共和国公司 法》《中华人民共和国证券法》《上市公司股权激励管理办法》《深圳证券交易 所创业板股票上市规则》《深圳证券交易所创业板上市公司自律监管指南第 1 号——业务办理》等其他有关法律、法规、规范性文件，以及《深圳开立生物医 疗科技股份有限公司章程》制订。 二、本激励计划采取的激励工具为限制性股票（第二类限制性股票）和股 票期权。股票来源为深圳开立生物医疗科技股份有限公司（以下简称"公司" 或"本公司"）向激励对象定向发行公司 A ...

Core Viewpoint - The article discusses the compliance requirements and conditions for the stock incentive plan of Saiwei Times Technology Co., Ltd, emphasizing the need for adherence to regulations and the importance of transparency in the implementation of such plans [1][3][4]. Compliance Requirements - The financial reports for the most recent accounting year did not receive a negative opinion or inability to express an opinion from registered accountants [3]. - There have been no instances in the last 36 months where profit distribution did not comply with laws, regulations, or company articles [3]. - The stock incentive plan must not exceed 20% of the company's total share capital in terms of the total number of shares involved [4][5]. Incentive Object Requirements - The incentive plan must not include shareholders holding more than 5% of the company's shares unless justified [3]. - No individuals have been identified as inappropriate candidates by the China Securities Regulatory Commission (CSRC) in the last 12 months [3]. - The plan must disclose the names, positions, and number of shares granted to directors and senior management [5][6]. Plan Disclosure Requirements - The stock incentive plan must clearly state its purpose, the basis for selecting incentive objects, and the number of rights to be granted [4][5]. - The plan must include details on the vesting period, grant date, and any conditions for exercising rights [5][6]. - The plan must ensure that the performance assessment indicators are objective, clear, and beneficial for enhancing the company's competitiveness [6][7]. Legal and Procedural Compliance - The company must ensure that the stock incentive plan complies with the "Management Measures for Stock Incentives" and that all procedures for drafting, reviewing, and publicizing the plan are followed [7][8]. - Independent financial advisors must provide complete and compliant professional opinions regarding the plan [11][12].

Core Viewpoint - Shenzhen Kaili Biomedical Technology Co., Ltd. is implementing a stock incentive plan to attract and retain talent, aligning the interests of shareholders, the company, and employees for long-term development [1][2]. Summary by Sections 1. Purpose of Assessment - The assessment aims to establish a long-term incentive mechanism to attract and retain talent, enhancing employee motivation and creativity while aligning the interests of shareholders, the company, and employees [1]. 2. Principles of Assessment - The assessment must adhere to principles of fairness, openness, and impartiality, closely linking the stock incentive plan with the performance and contributions of the incentivized individuals to maximize the interests of the company and all shareholders [2]. 3. Assessment Targets - The assessment applies to all participants in the stock incentive plan, including certain directors, senior management, middle management, and key technical personnel, excluding independent directors, supervisors, foreign employees, and shareholders holding more than 5% of the company's shares [2]. 4. Assessment Organization - The Board of Directors' Compensation and Assessment Committee is responsible for organizing and reviewing the assessment, while a working group composed of the Board Office, Human Resources Department, and Finance Department will implement the assessment [2]. 5. Assessment Indicators and Standards - The performance assessment for the stock incentive plan spans from 2025 to 2028, with specific net profit growth targets set for each year based on the 2024 net profit of 136.49 million yuan, requiring growth rates of at least 30% in 2025, 70% in 2026, 150% in 2027, and 260% in 2028 [3]. 6. Implementation of the Plan - If the company fails to meet the performance targets in any assessment year, the corresponding restricted stocks and stock options for that year will not vest or be exercised, and will be rendered void [3][4]. 7. Assessment Period and Frequency - The assessment period for the stock incentive plan is set for four accounting years from 2025 to 2028, with assessments conducted annually [4]. 8. Assessment Procedure - The assessment working group collects relevant business and financial data, evaluates whether the company and individuals meet the performance targets, and submits a performance assessment report to the Compensation and Assessment Committee [4][5]. 9. Management of Assessment Results - Assessment results will be communicated to the assessed individuals within seven working days, allowing for appeals, which must be reviewed within five working days [5].

Core Viewpoint - The company has repurchased a total of 19.5039 million shares, representing approximately 0.79% of its total share capital, with a total transaction amount of RMB 251 million, excluding transaction fees [1] Group 1 - The share repurchase is in line with the company's established plan and relevant laws and regulations [1] - The repurchased shares are intended for employee stock ownership plans or equity incentives to enhance long-term incentive mechanisms [1] - The initiative aims to strengthen team cohesion and competitiveness, promoting the company's long-term development [1]

Core Viewpoint - The incentive plan of Xiamen Tebao Biological Engineering Co., Ltd. involves the allocation of restricted stocks to 372 individuals, with a total of 1.2 million shares reserved for distribution, representing 0.29% of the total share capital at the time of the plan's submission to the shareholders' meeting [1] Group 1 - The total number of restricted stocks granted to the incentive recipients is 1.2 million shares [1] - The reserved shares account for 100% of the total reserved grant of restricted stocks [1] - The total number of shares involved in the incentive plan does not exceed 1% of the company's total share capital at the time of the plan's submission [1]

Core Viewpoint - The announcement details the results of the stock incentive plan for the first category of incentive objects' fourth vesting period and the second category's third vesting period, highlighting the failure of certain stocks to vest due to performance targets not being met and the departure of some incentive objects [1][8][9]. Group 1: Stock Incentive Plan Overview - The stock incentive plan was approved during the board meeting on May 28, 2020, and subsequently ratified by the shareholders on June 19, 2020 [1][3]. - The plan included a public notice period from June 1 to June 11, 2020, during which no objections were raised regarding the incentive objects [2]. Group 2: Vesting Results - For the first category of incentive objects, 38.825 thousand shares failed to vest due to 11 individuals leaving the company and the company's failure to meet the performance targets for the fourth vesting period [7][8]. - For the second category of incentive objects, 14.6025 thousand shares failed to vest due to one individual leaving and not meeting the performance targets for the third vesting period [8][9]. Group 3: Impact of Non-Vesting - The non-vesting of these shares is not expected to materially impact the company's financial status or operational results, nor will it affect the stability of the core management team [9].

Core Viewpoint - The legal opinion letter confirms that Nanjing Julong Technology Co., Ltd. has obtained the necessary approvals and authorizations for the adjustment and initial grant of the 2025 second phase restricted stock incentive plan, in compliance with relevant laws and regulations [4][11]. Summary by Sections Approval and Authorization - The company has completed the necessary procedures for the adjustment and initial grant of the incentive plan, including meetings of the compensation and assessment committee, board of directors, and supervisory board, all of which approved relevant proposals [4][5][6]. Adjustment of Grant Price - The grant price of the restricted stock was adjusted from 13.21 to 12.96 yuan per share due to a cash dividend distribution of 2.5 yuan per 10 shares, which was approved at the 2024 annual general meeting [7][8]. Grant Conditions - The initial grant conditions have been met, with no disqualifying events occurring for the incentive objects, such as negative audit opinions or regulatory penalties [9][11]. Grant Details - The initial grant date is set for September 5, 2025, with a grant price of 12.96 yuan per share for 635,000 shares to 10 incentive objects, as authorized by the board of directors [10][11].

证券代码：688278 证券简称：特宝生物 公告编号：2025- 厦门特宝生物工程股份有限公司 关于向 2024 年限制性股票激励计划激励对象 授予预留部分限制性股票的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 ? 限 制 性 股 票 预 留 授 予 数 量 ： 120.00 万 股 ， 占 目 前 公 司 股 本 总 额 重要内容提示： ? 股权激励方式：第二类限制性股票 ? 限制性股票预留授予日：2025 年 9 月 4 日 厦门特宝生物工程股份有限公司（以下简称"公司"）《2024 年限制性股 票激励计划（草案）》（以下简称"《激励计划（草案）》"或"本激励计划"） 规定的限制性股票授予条件已经成就，根据公司 2024 年第一次临时股东大会的 授权，公司于 2025 年 9 月 4 日分别召开第九届董事会第十一次会议和第九届监 事会第八次会议，审议通过了《关于向 2024 年限制性股票激励计划激励对象授 予预留部分限制性股票的议案》，确定 2025 年 9 月 4 日为预留授予日，以 39.18 元/股的授 ...